Literature DB >> 29076779

Cigarette smoking and outcomes after aneurysmal subarachnoid hemorrhage: a nationwide analysis.

Hormuzdiyar H Dasenbrock, Robert F Rudy, Pui Man Rosalind Lai, Timothy R Smith, Kai U Frerichs, William B Gormley, M Ali Aziz-Sultan, Rose Du.   

Abstract

OBJECTIVE Although cigarette smoking is one of the strongest risk factors for cerebral aneurysm development and rupture, there are limited data evaluating the impact of smoking on outcomes after aneurysmal subarachnoid hemorrhage (SAH). Additionally, two recent studies suggested that nicotine replacement therapy was associated with improved neurological outcomes among smokers who had sustained an SAH compared with smokers who did not receive nicotine. METHODS Patients who underwent endovascular or microsurgical repair of a ruptured cerebral aneurysm were extracted from the Nationwide Inpatient Sample (NIS, 2009-2011) and stratified by cigarette smoking. Multivariable logistic regression analyzed in-hospital mortality, complications, tracheostomy or gastrostomy placement, and discharge to institutional care (a nursing or an extended care facility). Additionally, the composite NIS-SAH outcome measure (based on mortality, tracheostomy or gastrostomy, and discharge disposition) was evaluated, which has been shown to have excellent agreement with a modified Rankin Scale score greater than 3. Covariates included in regression constructs were patient age, sex, race/ethnicity, insurance status, socioeconomic status, comorbidities (including hypertension, drug and alcohol abuse), the NIS-SAH severity scale (previously validated against the Hunt and Hess grade), treatment modality used for aneurysm repair, and hospital characteristics. A sensitivity analysis was performed matching smokers to nonsmokers on age, sex, number of comorbidities, and NIS-SAH severity scale score. RESULTS Among the 5784 admissions evaluated, 37.1% (n = 2148) had a diagnosis of tobacco use, of which 31.1% (n = 1800) were current and 6.0% (n = 348) prior tobacco users. Smokers were significantly younger (mean age 51.4 vs 56.2 years) and had more comorbidities compared with nonsmokers (p < 0.001). There were no significant differences in mortality, total complications, or neurological complications by smoking status. However, compared with nonsmokers, smokers had significantly decreased adjusted odds of tracheostomy or gastrostomy placement (11.9% vs 22.7%, odds ratio [OR] 0.63, 95% confidence interval [CI] 0.51-0.78, p < 0.001), discharge to institutional care (OR 0.71, 95% CI 0.57-0.89, p = 0.002), and a poor outcome (OR 0.65, 95% CI 0.55-0.77, p < 0.001). Similar statistical associations were noted in the matched-pairs sensitivity analysis and in a subgroup of poor-grade patients (the upper quartile of the NIS-SAH severity scale). CONCLUSIONS In this nationwide study, smokers experienced SAH at a younger age and had a greater number of comorbidities compared with nonsmokers, highlighting the negative ramifications of cigarette smoking among patients with cerebral aneurysms. However, smoking was also associated with paradoxical superior outcomes on some measures, and future research to confirm and further understand the basis of this relationship is needed.

Entities:  

Keywords:  ASA = American Society of Anesthesiologists; CI = confidence interval; COPD = chronic obstructive pulmonary disease; GOS = Glasgow Outcome Scale; NIS = Nationwide Inpatient Sample; NSQIP = National Surgical Quality Improvement Program; Nationwide Inpatient Sample; OR = odds ratio; SAH = subarachnoid hemorrhage; cerebral aneurysm; nicotine; outcomes; smoking; subarachnoid hemorrhage; tobacco; vascular disorders

Mesh:

Year:  2017        PMID: 29076779     DOI: 10.3171/2016.10.JNS16748

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  7 in total

1.  Impact of smoking on course and outcome of aneurysmal subarachnoid hemorrhage.

Authors:  H Slettebø; T Karic; A Sorteberg
Journal:  Acta Neurochir (Wien)       Date:  2020-07-30       Impact factor: 2.216

2.  Neurocritical care complications and interventions influence the outcome in aneurysmal subarachnoid hemorrhage.

Authors:  Alexander Hammer; Frank Erbguth; Matthias Hohenhaus; Christian M Hammer; Hannes Lücking; Markus Gesslein; Monika Killer-Oberpfalzer; Hans-Herbert Steiner; Hendrik Janssen
Journal:  BMC Neurol       Date:  2021-01-19       Impact factor: 2.474

3.  The Relationship Between Smoking and Delayed Cerebral Ischemia After Intracranial Aneurysm Rupture: A Systematic Review and Meta-Analysis.

Authors:  Xiaolong Ya; Chaoqi Zhang; Shuo Zhang; Qian Zhang; Yong Cao; Shuo Wang; Jizong Zhao
Journal:  Front Neurol       Date:  2021-03-26       Impact factor: 4.003

4.  Edema Resolution and Clinical Assessment in Poor-Grade Subarachnoid Hemorrhage: Useful Indicators to Predict Delayed Cerebral Infarctions?

Authors:  Ramon Torné; Jhon Hoyos; Laura Llull; Ana Rodríguez-Hernández; Guido Muñoz; Ricard Mellado-Artigas; Daniel Santana; Leire Pedrosa; Alberto Di Somma; Luis San Roman; Sergio Amaro; Joaquim Enseñat
Journal:  J Clin Med       Date:  2021-01-17       Impact factor: 4.241

5.  Mortality among patients treated for aneurysmal subarachnoid hemorrhage in Eastern Denmark 2017-2019.

Authors:  Agnes T Stauning; Frank Eriksson; Goetz Benndorf; Anders V Holst; John Hauerberg; Trine Stavngaard; Lars Poulsgaard; Per Rochat; Vagn Eskesen; Peter Birkeland; Tiit Mathiesen; Tina N Munch
Journal:  Acta Neurochir (Wien)       Date:  2022-07-22       Impact factor: 2.816

6.  Nicotine Replacement Therapy for Smokers with Acute Aneurysmal Subarachnoid Hemorrhage: An International Survey.

Authors:  Christian V Eisenring; Preci L Hamilton; Bawarjan Schatlo; David Nanchen; Philippe Herzog; Markus F Oertel; Isabelle Jacot-Sadowski; Felice Burn; Jacques Cornuz
Journal:  Adv Ther       Date:  2022-09-19       Impact factor: 4.070

7.  Risk Factors for Unfavorable Outcome in Aneurysmal Subarachnoid Hemorrhage Revisited; Odds and Ends.

Authors:  Abdolkarim Rahmanian; Nima Derakhshan; Alireza Mohsenian Sisakht; Najme Karamzade Ziarati; Hadi Raeisi Shahraki; Soheil Motamed
Journal:  Bull Emerg Trauma       Date:  2018-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.